Supplements That May Help With Pancreatitis Risk on Mounjaro (Tirzepatide)
At a glance
- Pancreatitis risk in pooled trials / not significantly increased with tirzepatide (RR 1.46, 95% CI 0.59 to 3.61) [1]
- Supplement evidence / no supplement dose or schedule for preventing pancreatitis is established on Mounjaro [2]
- Label warning / acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has been observed with GLP-1 receptor agonists or Mounjaro [2]
- Label instruction / discontinue Mounjaro if pancreatitis is suspected and initiate appropriate management [2]
- Real-world data / no clear increase in severe events such as pancreatitis in observational studies [3]
Does tirzepatide actually increase pancreatitis risk?
The Mounjaro label states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or with Mounjaro [2].
The controlled trial data do not show a significant increase. A 2023 systematic review and meta-analysis pooled nine randomized trials with 9,871 participants and found no statistically significant rise in pancreatitis with tirzepatide compared with placebo, basal insulin, dulaglutide or semaglutide (RR 1.46, 95% CI 0.59 to 3.61) [1]. A meta-analysis of 21 trials and 99,599 patients found no difference in pancreatitis between GLP-1 receptor agonists, tirzepatide included, and controls [4]. A 2025 review of real-world data likewise found no clear increase in severe events such as pancreatitis among people using these drugs [3].
Do any supplements lower the risk?
No supplement dose or schedule for preventing pancreatitis is established for people taking Mounjaro, and the Mounjaro label does not recommend any supplement for it [2]. The tirzepatide pancreatitis meta-analysis tested the drug against placebo and active comparators, not supplements [1].
What does the label say to watch for?
After starting Mounjaro, the label says to observe patients carefully for signs and symptoms of acute pancreatitis: persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [2]. The label's instruction is to discontinue Mounjaro if pancreatitis is suspected and to initiate appropriate management [2].
Frequently asked questions
How common is pancreatitis with Mounjaro?
Which pancreatitis symptoms does the Mounjaro label list?
References
- Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
- U.S. National Library of Medicine, DailyMed. Mounjaro injection and KwikPen (tirzepatide) prescribing information. Mounjaro injection and KwikPen (tirzepatide) label
- Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27 Suppl 2(Suppl 2):66-88. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies
- Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025;86(20):1805-1819. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients